303 related articles for article (PubMed ID: 24682509)
1. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.
Compagno N; Cinetto F; Semenzato G; Agostini C
Haematologica; 2014 Jun; 99(6):1101-6. PubMed ID: 24682509
[TBL] [Abstract][Full Text] [Related]
2. Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia.
Spadaro G; Pecoraro A; De Renzo A; Della Pepa R; Genovese A
Clin Immunol; 2016 May; 166-167():103-4. PubMed ID: 27063866
[TBL] [Abstract][Full Text] [Related]
3. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.
Casulo C; Maragulia J; Zelenetz AD
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):106-11. PubMed ID: 23276889
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial.
Vacca A; Melaccio A; Sportelli A; Solimando AG; Dammacco F; Ria R
Clin Immunol; 2018 Jun; 191():110-115. PubMed ID: 29191714
[TBL] [Abstract][Full Text] [Related]
5. Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia.
Otremba MD; Adam SI; Price CC; Hohuan D; Kveton JF
Am J Otolaryngol; 2012; 33(5):619-22. PubMed ID: 22361345
[TBL] [Abstract][Full Text] [Related]
6. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels.
Thépot S; Malphettes M; Gardeur A; Galicier L; Asli B; Karlin L; Gérard L; Laumont R; Doize ML; Arnulf B; Fieschi C; Bengoufa D; Oksenhendler E
J Clin Immunol; 2010 Jul; 30(4):602-6. PubMed ID: 20393788
[TBL] [Abstract][Full Text] [Related]
7. Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies.
Wiesik-Szewczyk E; Sołdacki D; Paczek L; Jahnz-Różyk K
Front Immunol; 2020; 11():981. PubMed ID: 32670265
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449
[TBL] [Abstract][Full Text] [Related]
9. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.
Marco H; Smith RM; Jones RB; Guerry MJ; Catapano F; Burns S; Chaudhry AN; Smith KG; Jayne DR
BMC Musculoskelet Disord; 2014 May; 15():178. PubMed ID: 24884562
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous IgG replacement therapy is safe and well tolerated in lung transplant recipients.
Shankar T; Gribowicz J; Crespo M; Silveira FP; Pilewski J; Petrov AA
Int Immunopharmacol; 2013 Apr; 15(4):752-5. PubMed ID: 23499641
[TBL] [Abstract][Full Text] [Related]
11. Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial.
Sarmiento E; Diez P; Arraya M; Jaramillo M; Calahorra L; Fernandez-Yañez J; Palomo J; Sousa I; Hortal J; Barrio J; Alonso R; Muñoz P; Navarro J; Vicario J; Fernandez-Cruz E; Carbone J
Transpl Infect Dis; 2016 Dec; 18(6):832-843. PubMed ID: 27639067
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.
Suez D; Stein M; Gupta S; Hussain I; Melamed I; Paris K; Darter A; Bourgeois C; Fritsch S; Leibl H; McCoy B; Gelmont D; Yel L
J Clin Immunol; 2016 Oct; 36(7):700-12. PubMed ID: 27582171
[TBL] [Abstract][Full Text] [Related]
14. Comparison of IVIg 5% Versus 10% in hematological patients with a secondary immunodeficiency disorder.
Van Ham J; Janssens A; Raddoux J; Raets E; Delforge M
Acta Clin Belg; 2021 Feb; 76(1):49-52. PubMed ID: 31422766
[No Abstract] [Full Text] [Related]
15. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
Berger M; Murphy E; Riley P; Bergman GE;
South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(
Angelotti F; Capecchi R; Giannini D; Mazzarella O; Rocchi V; Migliorini P
Clin Exp Med; 2020 Aug; 20(3):387-392. PubMed ID: 32385734
[TBL] [Abstract][Full Text] [Related]
17. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
McCormack PL
BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
[TBL] [Abstract][Full Text] [Related]
18. [Persistent hypogammaglobulinemia in an ITP patient following treatment with rituximab].
Toubi E
Harefuah; 2012 Nov; 151(11):620-1, 655. PubMed ID: 23367731
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases.
Ochs HD; Gupta S; Kiessling P; Nicolay U; Berger M;
J Clin Immunol; 2006 May; 26(3):265-73. PubMed ID: 16783465
[TBL] [Abstract][Full Text] [Related]
20. Hypogammaglobulinemia: therapeutic rationale.
Long AA; Denburg JA; Dent PB
CMAJ; 1987 Nov; 137(9):793-7. PubMed ID: 3327579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]